MARKET

CARA

CARA

Cara Therapeutic
NASDAQ
0.6900
-0.0419
-5.72%
After Hours: 0.6850 -0.005 -0.72% 17:53 04/18 EDT
OPEN
0.7300
PREV CLOSE
0.7319
HIGH
0.7361
LOW
0.6800
VOLUME
363.14K
TURNOVER
0
52 WEEK HIGH
4.670
52 WEEK LOW
0.5000
MARKET CAP
37.71M
P/E (TTM)
-0.3153
1D
5D
1M
3M
1Y
5Y
Bearish Sentiment Across The Cannabis Space - Check Full Movers For April 18, 2024
Shares of SOL Glb Inv (OTC:SOLCF) closed up 38.57% at $0.03. MJ Holdings and Canopy Gwth shares closed up 27.91% and 20.34% respectively. Australis Capital shares closed down 99.00%.
Benzinga · 15h ago
Bearish Monday For Marijuana Stocks - AusCann Group Holdings, Target Group Among Top Gainers
Target Group shares closed up 26.37% at $0.01. Greenlane Hldgs and Mexco Energy shares also closed up. AusCann Group Holdings shares closed down 77.68% in the last day. Canopy Gwth and Aurora Cannabis are among the companies losing ground.
Benzinga · 3d ago
Weekly Report: what happened at CARA last week (0408-0412)?
Weekly Report · 4d ago
Buy Rating Affirmed for Cara Therapeutics: Promising Prospects for Oral Difelikefalin in Notalgia Paresthetica Treatment
TipRanks · 04/12 10:16
CARA THERAPEUTICS, INC. <CARA.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $3.6 FROM $2.5
Reuters · 04/12 10:04
Buy Rating Affirmed for Cara Therapeutics Amidst Promising Korsuva Ph 2/3 Program and Market Potential
TipRanks · 04/10 10:35
Marijuana Stock Movers For April 8, 2024
GreenGro Technologies (OTC:GRNH) shares closed up 9900.00% at $0.01. AusCann Group Holdings closed up 387.78% in the last day. Global Hemp Group shares closed down 42.86% at the end of the day.
Benzinga · 04/08 20:30
Weekly Report: what happened at CARA last week (0401-0405)?
Weekly Report · 04/08 11:20
More
About CARA
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Webull offers Cara Therapeutics Inc stock information, including NASDAQ: CARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CARA stock methods without spending real money on the virtual paper trading platform.